---  
layout: startup_page  
title: "D3 Bio"  
id: "d3bio.com"  
permalink: "/d3biod3bio.com04082024/"  
website: "https://www.d3bio.com/"  
funding_round: "Series A+"  
funding_amount: "$62M"  
investors: "Medicxi, Matrix Partners China, WuXi AppTec's Corporate Venture Fund"  
about: "D3 Bio is a clinical-stage biotechnology company focused on discovering, developing, and registering new oncology and immunology medicines. They leverage clinical insight and biomarker strategies to create novel therapies for patients. Their lead asset, D3S-001, is a next-generation KRAS G12C inhibitor currently in Phase II development."  
markets: "Biotechnology, Oncology, Immunology, Life Science, Pharmaceutical"  
hq: "Wuxi, Jiangsu, China"  
founded_year: "2018"  
linkedin: "https://www.linkedin.com/company/d3bio"  
twitter: ""  
instagram: ""  
facebook: ""  
crunchbase: "https://www.crunchbase.com/organization/d3-bio"  
pitchbook: "https://pitchbook.com/profiles/company/453472-39"  

date_display: "08-Apr-2024"  
date: "2024-04-08"

# SEO Optimization  
meta_title: "D3 Bio - Series A+ Funding ($62M)"  
meta_description: "D3 Bio, D3 Bio is a clinical-stage biotechnology company focused on discovering, developing, and registering new oncology and immunology medicines. They lever..."  
meta_keywords: "D3 Bio, Biotechnology, Oncology, Immunology, Life Science, Pharmaceutical, Series A+ funding"  
canonical_url: "https://startup.projectstartups.com/d3biod3bio.com04082024/"  
---